Nuclear p53 accumulation by small-sized adenocarcinomas of the lung

被引:29
作者
Kawasaki, M
Noguchi, M
Morikawa, A
Matsuno, Y
Yamada, T
Hirohashi, S
Kondo, H
Shimosato, Y
机构
[1] NATL CANC CTR,RES INST,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN
[2] NATL CANC CTR,DIV SURG,TOKYO,JAPAN
[3] NATL CANC CTR,CLIN LAB DIV,TOKYO,JAPAN
关键词
lung adenocarcinoma; nuclear p53 accumulation; tumor progression;
D O I
10.1111/j.1440-1827.1996.tb03642.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In order to evaluate the alterations of nuclear p53 accumulation in early stage adenocarcinomas of the lung, nuclear p53 accumulation by small-sized peripheral adenocarcinomas of the lung was examined immunohistochemically. Peripheral adenocarcinomas of the lung, 2 cm or less in diameter, have been classified into two groups; one showing replacing growth of the pulmonary alveolar structure and the other showing non-replacing growth, The former group has been subdivided into three microscopic subtypes: type A, localized bronchioloalveolar carcinoma (LBAC); B, LBAC with foci of pulmonary alveolar structural collapse; and C, LBAC with foci of active fibroblastic proliferation. Type C is thought to be advanced carcinoma, which develops progressively from types A and B. Two of 32 (6%) types A and B carcinomas, 37 of 133 (28%) type C carcinomas and 14 of 35 (40%) non-replacement-type adenocarcinomas showed positive nuclear staining for p53. The positive staining frequency was significantly higher for type C than for types A and B (P < 0.05). These results suggest that nuclear p53 accumulation occurs in the transition from the early to advanced stages of replacement-type adenocarcinoma development and it may be a clinically useful indicator of the degree of tumor malignancy.
引用
收藏
页码:486 / 490
页数:5
相关论文
共 26 条
[1]  
BAKER SJ, 1990, CANCER RES, V50, P7717
[2]   ABNORMAL EXPRESSION OF WILD TYPE-P53 PROTEIN IN NORMAL-CELLS OF A CANCER FAMILY PATIENT [J].
BARNES, DM ;
HANBY, AM ;
GILLETT, CE ;
MOHAMMED, S ;
HODGSON, S ;
BOBROW, LG ;
LEIGH, IM ;
PURKIS, T ;
MACGEOCH, C ;
SPURR, NK ;
BARTEK, J ;
VOJTESEK, B ;
PICKSLEY, SM ;
LANE, DP .
LANCET, 1992, 340 (8814) :259-263
[3]  
CAMPBELL C, 1993, CANCER RES, V53, P2697
[4]   CLINICOPATHOLOGICAL SIGNIFICANCE OF NUCLEAR ACCUMULATION OF TUMOR SUPPRESSOR GENE-P53 PRODUCT IN PRIMARY LUNG-CANCER [J].
HIYOSHI, H ;
MATSUNO, Y ;
KATO, H ;
SHIMOSATO, Y ;
HIROHASHI, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (01) :101-106
[5]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[6]   INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER [J].
IGGO, R ;
GATTER, K ;
BARTEK, J ;
LANE, D ;
HARRIS, AL .
LANCET, 1990, 335 (8691) :675-679
[7]   NUCLEAR P53 IMMUNOREACTION ASSOCIATED WITH POOR PROGNOSIS OF BREAST-CANCER [J].
IWAYA, K ;
TSUDA, H ;
HIRAIDE, H ;
TAMAKI, K ;
TAMAKUMA, S ;
FUKUTOMI, T ;
MUKAI, K ;
HIROHASHI, S .
JAPANESE JOURNAL OF CANCER RESEARCH, 1991, 82 (07) :835-840
[8]   SURGICALLY CURABLE EARLY ADENOCARCINOMA IN THE PERIPHERY OF THE LUNG [J].
KUROKAWA, T ;
MATSUNO, Y ;
NOGUCHI, M ;
MIZUNO, S ;
SHIMOSATO, Y .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1994, 18 (05) :431-438
[9]   THE P53 TUMOR SUPPRESSOR GENE [J].
LEVINE, AJ ;
MOMAND, J ;
FINLAY, CA .
NATURE, 1991, 351 (6326) :453-456
[10]   P53 EXPRESSION AND PROGNOSIS IN GASTRIC-CARCINOMA [J].
MARTIN, HM ;
FILIPE, MI ;
MORRIS, RW ;
LANE, DP ;
SILVESTRE, F .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (06) :859-862